AIM: To assess the predictive value of baseline ventricular dyssynchrony and myocardial contractile reserve (mCR) in identifying responders to cardiac resynchronization therapy (CRT). METHODS: We prospectively studied 57 patients selected for CRT according to current recommendations. Regional dyssynchrony was evaluated by parametric phase imaging of ecg-gated equilibrium radionuclide angiography (ERNA). The mean inter-ventricular phase delay and the standard deviation to mean left ventricular (LV) phase angle were used as a measure of inter- and intra-ventricular dyssynchrony, respectively. Change in LV ejection fraction (LVEF) during low-dose dobutamine (LDD) was measured to assess mCR. ERNA was repeated at 6 months to evaluate changes in LVEF after CRT. Combined end-points of re-hospitalization for heart failure, heart transplantation, and cardiac death were assessed over a period of 76 months (mean 43 ± 31). RESULTS: Baseline dyssynchrony was present in most patients (85%). After CRT only one half of patients showed a reduction in intra-ventricular dyssynchrony and 33% an increase in LVEF by >5%. Improvement of LVEF was not predicted by baseline LVEF, clinical presentation, dyssynchrony parameters or QRS duration. There was a significant relationship between changes in LVEF during LDD testing and after CRT (r = 0.65; P < .0001). Logistic regression analysis identified mCR as independent predictor of improvement in LVEF (P = .039; OR = 3.84; CI 95% = 1.06-13.9), resynchronization (P = .046; OR = 4.20; CI 95% = 1.03-17.2), and event-free survival (P = .002; OR = 0.10; CI 95% = 0.02-0.43). CONCLUSIONS: In patients with left ventricular dysfunction and baseline dyssynchrony as assessed by ERNA, evaluation of mCR during LDD may help predicting functional improvement and selecting potential responders to CRT.
AIM: To assess the predictive value of baseline ventricular dyssynchrony and myocardial contractile reserve (mCR) in identifying responders to cardiac resynchronization therapy (CRT). METHODS: We prospectively studied 57 patients selected for CRT according to current recommendations. Regional dyssynchrony was evaluated by parametric phase imaging of ecg-gated equilibrium radionuclide angiography (ERNA). The mean inter-ventricular phase delay and the standard deviation to mean left ventricular (LV) phase angle were used as a measure of inter- and intra-ventricular dyssynchrony, respectively. Change in LV ejection fraction (LVEF) during low-dose dobutamine (LDD) was measured to assess mCR. ERNA was repeated at 6 months to evaluate changes in LVEF after CRT. Combined end-points of re-hospitalization for heart failure, heart transplantation, and cardiac death were assessed over a period of 76 months (mean 43 ± 31). RESULTS: Baseline dyssynchrony was present in most patients (85%). After CRT only one half of patients showed a reduction in intra-ventricular dyssynchrony and 33% an increase in LVEF by >5%. Improvement of LVEF was not predicted by baseline LVEF, clinical presentation, dyssynchrony parameters or QRS duration. There was a significant relationship between changes in LVEF during LDD testing and after CRT (r = 0.65; P < .0001). Logistic regression analysis identified mCR as independent predictor of improvement in LVEF (P = .039; OR = 3.84; CI 95% = 1.06-13.9), resynchronization (P = .046; OR = 4.20; CI 95% = 1.03-17.2), and event-free survival (P = .002; OR = 0.10; CI 95% = 0.02-0.43). CONCLUSIONS: In patients with left ventricular dysfunction and baseline dyssynchrony as assessed by ERNA, evaluation of mCR during LDD may help predicting functional improvement and selecting potential responders to CRT.
Authors: M W Groch; E G DePuey; A C Belzberg; W D Erwin; M Kamran; C A Barnett; R C Hendel; S M Spies; A Ali; R C Marshall Journal: J Nucl Med Date: 2001-12 Impact factor: 10.057
Authors: Gabriel Gregoratos; Jonathan Abrams; Andrew E Epstein; Roger A Freedman; David L Hayes; Mark A Hlatky; Richard E Kerber; Gerald V Naccarelli; Mark H Schoenfeld; Michael J Silka; Stephen L Winters Journal: J Am Coll Cardiol Date: 2002-11-06 Impact factor: 24.094
Authors: William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger Journal: N Engl J Med Date: 2002-06-13 Impact factor: 91.245
Authors: Ole A Breithardt; Christoph Stellbrink; Andrew P Kramer; Anil M Sinha; Andreas Franke; Rodney Salo; Bernhard Schiffgens; Etienne Huvelle; Angelo Auricchio Journal: J Am Coll Cardiol Date: 2002-08-07 Impact factor: 24.094
Authors: Panos E Vardas; Angelo Auricchio; Jean-Jacques Blanc; Jean-Claude Daubert; Helmut Drexler; Hugo Ector; Maurizio Gasparini; Cecilia Linde; Francisco Bello Morgado; Ali Oto; Richard Sutton; Maria Trusz-Gluza Journal: Eur Heart J Date: 2007-08-28 Impact factor: 29.983
Authors: John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Mark A Trimble; Salvador Borges-Neto; Emily F Honeycutt; Linda K Shaw; Robert Pagnanelli; Ji Chen; Ami E Iskandrian; Ernest V Garcia; Eric J Velazquez Journal: J Nucl Cardiol Date: 2008 Sep-Oct Impact factor: 5.952
Authors: Nathaniel M Hawkins; Mark C Petrie; Michael R MacDonald; Kerry J Hogg; John J V McMurray Journal: Eur Heart J Date: 2006-03-09 Impact factor: 29.983
Authors: Marie Moonen; Mario Senechal; Bernard Cosyns; Pierre Melon; Eric Nellessen; Luc Pierard; Patrizio Lancellotti Journal: Cardiovasc Ultrasound Date: 2008-12-31 Impact factor: 2.062
Authors: Vladimir V Shipulin; Sergey L Andreev; Andrew S Pryakhin; Andrew V Mochula; Alina N Maltseva; Svetlana I Sazonova; Vladimir M Shipulin; Samia Massalha; Konstantin V Zavadovsky Journal: Eur J Nucl Med Mol Imaging Date: 2022-02-12 Impact factor: 10.057